Remdesivir may not cure coronavirus, but it’s on track to make billions for Gilead

The commercial success of remdesivir, despite its narrow benefit for hospitalized coronavirus patients, highlights the lack of potent tools for doctors six months into the pandemic.

Leave a Reply

%d bloggers like this: